

City of Hope Division of Clinical Cancer Genetics Publications



Index

[2011](#), [2010](#), [2009](#), [2008](#), [2007](#), [2006](#), [2005](#), [2004](#)

2011

Beamer, L., Grant, M., Huizenga, C., Blazer, K., Hampel, H., Weitzel, J.N., & MacDonald, D.J. (2011 In-Press) **Reflex Immunohistochemistry and Microsatellite Instability Testing of Colorectal Tumors for Lynch Syndrome among US Cancer Programs and Follow-up of Abnormal Results.** *J Clin Oncol*.

Blazer, K. R., MacDonald, D. J., Culver, J. O., Huizenga, C. R., Morgan, R. J., Uman, G. C., & Weitzel, J. N. (2011). **Personalized cancer genetics training for personalized medicine: Improving community-based healthcare through a genetically literate workforce.** *Genet Med*. 13(9), 832-840. doi:10.1097/GIM.0b013e31821882b7

Brown, S. M., Culver, J. O., Osann, K. E., MacDonald, D. J., Sand, S., Thornton, A. A.,...Weitzel, J. N. (2011). **Health literacy, numeracy, and interpretation of graphical breast cancer risk estimates.** *Patient Educ Couns*, 83(1), 92-98. doi:10.1016/j.pec.2010.04.027

Clague J, Wilhoite G, Adamson A, Bailis A, Weitzel JN, Neuhausen SL. (2011 In Press) **RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.** *PLoS One*.

Culver, J. O., MacDonald, D. J., Thornton, A. A., Sand, S. S., Grant, M., Bowen, D. J.,...Weitzel, J. N. (2011). **Development and evaluation of a decision aid for BRCA carriers with breast cancer.** *J Gen Counsel*, 20(3), 294-307. doi:10.1007/s10897-011-9350-4

Huizenga, C., Martir-Negron, A., Blazer, K., Culver, J., MacDonald, D., & Weitzel, J. (2011). **Mind the gap: challenges in the clinical management of Lynch Syndrome families.** *Hered Cancer Clin Pr*, 9(Suppl 1), P16. doi:10.1186/1897-4287-9-S1-P16

Im, K. M., Kirchhoff, T., Wang, X., Green, T., Chow, C. Y., Vijai, J.,...Weitzel, J. N., et al. (2011). **Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers** [ePub ahead of print May 21, 2011]. *Hum Genet*. doi:10.1007/s00439-011-1003-z

Lagos-Jaramillo, V. I., Press, M. F., Ricker, C. N., Dubeau, L., Mai, P. L., & Weitzel, J. N. (2011). **Pathological characteristics of BRCA-associated breast cancers in Hispanics** [ePub ahead of print May 21, 2011]. *Breast Cancer Res Treat*. doi:10.1007/s10549-011-1570-7

MacDonald, D. J. (2011). **Germline Mutations in Cancer Susceptibility Genes: An Overview for Nurses.** *Semin Oncol Nurs*, 27(1), 21-33. doi:10.1016/j.soncn.2010.11.004

City of Hope

Division of Clinical Cancer Genetics

Publications

Neuhausen, S. L., Brummel, S., Ding, Y., Steele, L., Nathanson, K., Domchek, S. M., et al. (2011). **Genetic Variation in IGF2 and HTRA1 and Breast Cancer Risk Among BRCA1 and BRCA2 Carriers.** *Cancer Epidemiology, Biomarkers & Prevention*, 20(11), 1690-1702.

Rebbeck, T., Mitra, N., Domchek, S. M., Wan, F., Friebel, T. M., Tran, T. V.,...Weitzel, J.N., et al. (2011 ePub ahead of print) **Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes.** *Cancer Res.* 71(17), 5792-5805.

Sorrell, A. D., Lee, S., Stolle, C., Ellenhorn, J., Grix, A., Kaelin, W. G., Jr., & Weitzel, J. N. (2011). **Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.** *Clin Genet*, 79(6), 539-545. doi:10.1111/j.1399-0004.2010.01464.x

Spurdle, M., Marquart, L., McGuffog, L., Healey, S., Sinilnikova, O. M., Wan, F., ...Weitzel, J.N, et al. (2011). **Common genetic variation at BARD1 is not associated with Breast cancer risk in BRCA1 or BRCA2 mutation carriers.** *Cancer Epidem Biomar*, 20(5), 1032-1038. doi:10.1158/1055-9965.EPI-10-0909

Weitzel, J. N., Blazer, K. R., MacDonald, D. J., Culver, J. O., & Offit, K. (2011) **Genetics, Genomics and Cancer Risk Assessment: State of the art and future directions in the era of personalized medicine.** *CA-Cancer J Clin*, 61(5), 327-359. doi:10.3322/caac.20128

2010

Allain, D., Baker, M., Blazer, K. R., Cohen, S., Copeland, K., Djurdjinovic, L., et al. (2010). **Evolving models of cancer risk genetic counseling.** *Perspectives in Genetic Counseling*, 32(1), 14-17. Retrieved from <http://www.nsgc.org/source/security/member-logon.cfm?section=home>

Antoniou, A. C., Wang, X., Fredericksen, Z. S., McGuffog, L., Tarrell, R., Sinilnikova, O. M.,...Weitzel, J. N., et al. (2010). **A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.** *Nat Genet*, 42(10), 885-892. doi:10.1038/ng.669

Antoniou, A. C., Beesley, J., McGuffog, L., Sinilnikova, O. M., Healey, S., Neuhausen, S. L.,...Weitzel, J. N, et al. (2010). **Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: Implications for risk prediction.** *Cancer Res*, 70(23), 9742-9754. doi:10.1158/0008-5472.CAN-10-1907

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M.,...Weitzel, J. N., et al. (2010). **Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial.** *Lancet*, 376(9737), 211-213. doi:10.1016/S0140-6736(10)60893-8

Blazer, K. R., Clague, J., Collie, C. L., Ciadella-Kam, L. A., Kuratani, D. G., Laird, S. L., et al. (2010). **"Future directions in cancer prevention and control: Workforce implications for training, practice, and policy" Symposium, October 17 to 18, 2009, the University of**

City of Hope

Division of Clinical Cancer Genetics

Publications

Texas M. D. Anderson Cancer Center. *Cancer Epidemiol Biomarkers Prev*, 19(6), 1655-1660. doi:10.1158/1055-9965.EPI-10-0441

Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S.,...Weitzel, J. N. (2010). **Genetic/familial high-risk assessment: Breast and ovarian.** *J Natl Compr Canc Netw*, 8(5), 562-594.

Domchek, S. M., Friebel, T. M., Garber, J. E., Isaacs, C., Matloff, E., Eeles, R.,...Weitzel, J. N., et al. (2010). **Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.** *Breast Cancer Res Treat*, 124(1), 195-203. doi:10.1007/s10549-010-0799-x

Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C.,...Weitzel, J. N., et al. (2010). **Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.** *JAMA*, 304(9), 967-975. doi:10.1001/jama.2010.1237

Gaudet, M. M., Kirchhoff, T., Green, T., Vijai, J., Korn, J. M., Guiducci, C.,...Weitzel, J. N., et al. (2010). **Common genetic variants and modification of penetrance of BRCA2-associated breast cancer.** *PLoS Genet*, 6(10), e1001183. doi:10.1371/journal.pgen.1001183

Huizenga, C. R., Lowstuter, K. J., Banks, K. C., Lagos, V. I., Vandergon, V. O., & Weitzel, J. N. (2010). **Evolving perspectives on genetic discrimination in health insurance among health care providers.** *Fam Cancer*, 9, 253-260. doi:10.1007/s10689-009-9308-y

Jasperson, K., Vu, T. M., Schwab, A. L., Neklason, D. W., Rodriguez-Bigas, M. A., Burt, R. W., & Weitzel, J. N. (2010). **Evaluating Lynch Syndrome in very early onset colorectal cancer probands without apparent polyposis.** *Fam Cancer*, 9(2), 99-107. doi:10.1007/s10689-009-9290-4

Kempers, M. J., Kuiper, R. P., Ockeloen, C. W., Chappuis, P. O., Hutter, P., Rahner, N.,...Culver, J. O., et al. (2010). **Risk of colorectal and endometrial cancers in epcam deletion-positive Lynch Syndrome: A cohort study.** *Lancet Oncol*. doi:10.1016/S1470-2045(10)70265-5

MacDonald, D. J. (2010). **Establishing a cancer genetics service.** In H. Kuerer (Ed.), *Kuerer's breast surgical oncology*. New York, NY: McGraw-Hill.

MacDonald, D. J., Blazer, K. R., & Weitzel, J. N. (2010). **Extending comprehensive cancer center expertise in clinical cancer genetics and genomics to diverse communities: The power of partnership.** *J Natl Compr Canc Netw*, 8(5), 615-624.

MacDonald, D. J., Sarna, L., Weitzel, J. N., & Ferrell, B. (2010). **Women's perceptions of the personal and family impact of genetic cancer risk assessment: Focus group findings.** *J Genet Couns*, 19(2), 148-160. doi:10.1007/s10897-009-9267-3

Robson, M. E., Storm, C. D., Weitzel, J. N., Wollins, D. S., & Offit, K. (2010). **American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility.** *J Clin Oncol*, 28(5), 893-901. doi:10.1200/JCO.2009.27.0660

City of Hope

Division of Clinical Cancer Genetics

Publications

Stadler, Z. K., Thom, P., Robson, M. E., Weitzel, J. N., Kauff, N. D., Hurley, K. E., et al. (2010). **Genome-wide association studies of cancer.** *J Clin Oncol*, 28(27), 4255-4267. doi:10.1200/JCO.2009.25.7816

Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., et al. (2010). **Oral poly (adp-ribose) polymerase inhibitor olaparib in patients with *BRCA1* or *BRCA2* mutations and advanced breast cancer: A proof-of-concept trial.** *Lancet*, 376(9737), 211-213. doi:10.1016/S0140-6736(10)60892-6

2009

Gonzalez KDF, Weitzel JN, Sommer SS. (2009) **Reply to J. Tinat.** *J Clin Oncol*. 27(26): E110. doi:10.1200/JCO.2009.22.8353

Gonzalez, K. D., Noltner, K. A., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Nguyen, V. Q.,...Weitzel, J. N. (2009). **Beyond Li –Fraumeni Syndrome: Clinical characteristics of families with p53 germline mutations.** *J Clin Oncol*, 27(8), 1250-1256. doi:10.1200/JCO.2008.16.6959

McKinnon, W., Banks, K. C., Skelly, J., Kohlmann, W., Bennett, R., Shannon, K.,...Weitzel, J. N., et al. (2009). **Survey of unaffected *BRCA* and mismatch repair (MMR) mutation positive individuals.** *Fam Cancer*, 8(4), 363-369. doi:10.1007/s10689-009-9248-6

Neuhausen, S. L., Brummel, S., Ding, Y. C., Singer, C. F., Pfeiler, G., Lynch, H. T.,...Weitzel, JN, et al. (2009). **Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among *BRCA1* and *BRCA2* carriers.** *Breast Cancer Res*, 11(5), R76. doi:10.1186/bcr2414

Pal, S. K., Blazer, K. R., Weitzel, J. N., & Somlo, G. (2009). **An association between invasive breast cancer and familial idiopathic hyperparathyroidism: A case series and review of the literature.** *Breast Cancer Res Treat*, 115: 1-5.

Rebbeck, T. R., Mitra, N., Domchek, S. M., Wan, F., Chuai, S., Friebel, T. M.,...Weitzel, J. N., et al. (2009). **Modification of ovarian cancer risk by *BRCA1/2*-interacting genes in a multicenter cohort of *BRCA1/2* mutation carriers.** *Cancer Res*, 69(14), 5801-5810. doi:10.1158/0008-5472.CAN-09-0625

Torres, D., Rashid, M. U., Seidel-Renkert, A., Weitzel, J. N., Briceno, I., & Hamann, U. (2009). **Absence of the *BRCA1* del (exons 9-12) mutation in breast/ovarian cancer families outside of Mexican Hispanics.** *Breast Cancer Res Treat*, 117(3), 679-681. doi:10.1007/10549-009-0383-4

2008

Antoniou, A. C., Spurdle, A. B., Sinilnikova, O. M., Healey, S., Pooley, K. A., Schmutzler, R. K.,...Weitzel, J. N., et al. (2008). **Common breast cancer-predisposition alleles are**

City of Hope

Division of Clinical Cancer Genetics

Publications

associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Am J Hum Genet*, 82(4), 937-948. doi:10.1016/j.ajhg.2008.02.008

Jasperson, K. W., Blazer, K. R., Lowstuter, K. J., & Weitzel, J. N. (2008). **Working through a diagnostic challenge: Colonic polyposis, Amsterdam criteria, and a mismatch repair mutation.** *Fam Cancer*, 7(4), 281-285. doi:10.1007/s10689-007-9179-z

Lagos, V. I., Perez, M. A., Ricker, C. N., Blazer, K. R., Santiago, N. M., Feldman, N.,...Weitzel, J. N. (2008). **Social cognitive aspects of underserved Latinas preparing to undergo genetic risk assessment for hereditary breast and ovarian cancer.** *Psycho-oncol*, 17(8), 774-782. doi:10.1002/pon.1358

Lowstuter, K. J., Sand, S., Blazer, K. R., MacDonald, D. J., Banks, K. C., Lee, C. A., et al. (2008). **Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians.** *Genet Med*, 10(9), 691-698. doi:10.1097/GIM.0b013e3181837246

MacDonald, D. J., Sarna, L., Giger, J. N., Bastani, R., van Servellen, G., & Weitzel, J. N. (2008). **Comparison of Latina and non-Latina white women's beliefs about communicating genetic cancer risk to relatives.** *J Health Commun*, 13(5), 465-479. doi:10.1080/10810730802198920

Mai, P. L., Lagos, V. I., Palomares, M. R., & Weitzel, J. N. (2008). **Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment.** *Ann Surg Oncol*, 15(12), 3415-3421. doi:10.1245/s10434-008-0160-3

Maradiegue, A., Jasperson, K. W., Edwards, Q. T., Lowstuter, K. J., & Weitzel, J. N. (2008). **Scoping the family history: Assessment of Lynch Syndrome (hereditary nonpolyposis colorectal cancer) in primary care settings—A primer for nurse practitioners.** *J Am Acad Nurse Pract*, 20(2), 76-84. doi:10.1111/j.1745-7599.2007.00282.x

Metcalfe, K. A., Lubinski, J., Ghadirian, P., Lynch, H., Kim-Sing, C., Friedman, E.,...Weitzel, J. N., et al. (2008). **Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: The Hereditary Breast Cancer Clinical Study Group.** *J Clin Oncol*, 26(7), 1093-1097. doi:10.1200/JCO.2007.12.6078

West, J. G., Weitzel, J. N., Tao, M. L., Carpenter, M., West, J. E., & Fanning, C. (2008). **BRCA1/2 mutations and the risk of angiosarcoma following breast cancer treatment.** *Clin Breast Cancer*, 8(6), 533-537. doi:10.3816/CBC.2008.n.066

2007

Antoniou, A. C., Sinilnikova, O. M., Simard, J., Leone, M., Dumont, M., Neuhausen, S. L.,...Weitzel, J. N., et al. (2007). **RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: Results from a combined analysis of 19 studies.** *Am J Hum Genet*, 81(6), 1186-1200. doi:10.1086/522611

City of Hope

Division of Clinical Cancer Genetics

Publications

Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Lawton T, Loftus L, MacDonald DJ, Mahoney MC, Merajver SD, Seewaldt V, Sellin RV, Shapiro CL, Singletary E, Ward JH. (2007) **Breast cancer risk reduction.** *J Natl Compr Canc Netw.* 5(8): 676-701.

Couch, F. J., Sinilnikova, O., Vierkant, R. A., Pankratz, V. S., Fredericksen, Z. S., Stoppa-Lyonnet, D.,...Weitzel, J. N., et al. (2007). **AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A CIMBA study.** *Cancer Epidemiol Biomarkers Prev*, 16(7), 1416-1421. doi:10.1158/1055-9965.EPI-07-0129

Culver, J. O., Lowstuter, K. J., & Bowling, L. G. (2007). **Assessing breast cancer risk and BRCA1/2 carrier probability.** *Breast Dis*, 27, 5-20.

Edwards, Q. T., Seibert, D., Maradiegue, A., MacDonald, D. J., Jasperson, K. W., Lowstuter, K. J., & Weitzel, J. N. (2007). **Breast cancer and the family tree: An issue for all practice settings.** *Adv Nurse Pract*, 15(5), 34-41.

Friebel, T. M., Domchek, S. M., Neuhausen, S. L., Wagner, T., Evans, D. G., Isaacs, C.,...Weitzel, J. N., et al. (2007). **Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.** *Clin Breast Cancer*, 7(11), 875-882.

Kotsopoulos, J., Lubinski, J., Lynch, H. T., Klijn, J., Ghadirian, P., Neuhausen, S. L.,...Weitzel, J. N., et al. (2007). **Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.** *Breast Cancer Res Treat*, 105(2), 221-228. doi:10.1007/s10549-006-9441-3

MacDonald, D. J., Sarna, L., van Servellen, G., Bastani, R., Giger, J. N., & Weitzel, J. N. (2007). **Selection of family members for communication of cancer risk and barriers to this communication before and after genetic cancer risk assessment.** *Genet Med*, 9(5), 275-282. doi:10.1097/GIM.0b013e31804ec075

Parmigiani, G., Chen, S., Iversen, E. S., Kligner, T. M., Finkelstein, D., Anton-Culver, H.,...Weitzel, J. N., et al. (2007). **Validity of models for prediction of BRCA1 and BRCA2 mutations.** *Ann Intern Med*, 147, No. 7, 441-450.

Ricker, C. N., Hiyama, S., Fuentes, S., Feldman, N., Kumar, V., Uman, G. C.,...Weitzel, J. N. (2007). **Beliefs and interest in cancer risk in an underserved Latino cohort.** *Prev Med*, 44(3), 241-245. doi:10.1016/j.ypmed.2006.08.018

Weitzel, J. N., Buys, S. S., Sherman, W. H., Daniels, A. M., Ursin, G., Daniels, J. R.,...MacDonald, D. J., Blazer, K. R., et al. (2007). **Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers.** *Clin Cancer Res*, 13(2), 654-658. doi:10.1158/1078-0432.CCR.06-1902

Weitzel, J. N., Lagos, V. I., Cullinane, C. A., Gambol, P. J., Culver, J. O., Blazer, K. R., Palomares, M. R., Lowstuter, K. J., & MacDonald, D. J. (2007). **Limited family structure and BRCA gene mutation status in single cases of breast cancer.** *JAMA*, 297(23), 2587-2595. doi:10.1001/jama.297.23.2587

City of Hope

Division of Clinical Cancer Genetics

Publications

Weitzel, J. N., Lagos, V. I., Herzog, J. S., Judkins, T., Hendrickson, B., Ho, J. S.,...Blazer, K. R., et al. (2007). **Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families.** *Cancer Epidemiol Biomarkers Prev*, 16(8), 1615-1620. doi:10.1158/1055-9965.EPI-07-0198

2006

Blazer, K. R., MacDonald, D. J., Justus, K. A., Grant, M., Azen, S. P., Chamberlain, R. M., et al. (2006). **Creating tomorrow's leaders in cancer prevention: A novel interdisciplinary career development program in cancer genetics research.** *J Cancer Educ*, 21(4), 216-222.

Daly, M. B., Axilbund, J. E., Bryant, E., Buys, S., Eng, C., Friedman, S., ...Weitzel, J. N. (2006). **Genetic/familial high-risk assessment: Breast and ovarian.** *J Natl Compr Canc Netw*, 4(2), 156-176.

Finch, A., Beiner, M., Lubinski, J., Lynch, H. T., Moller, P., Rosen, B.,...Weitzel, J. N., et al. (2006). **Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation.** *JAMA*, 296(2), 185-192. doi:10.1001/ama.296.2.185

Gronwald, J., Tung, N., Foulkes, W. D., Offit, K., Gershoni, R., Daly, M. B.,...Weitzel, J. N., et al. (2006). **Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update.** *Int J Cancer*, 118(9), 2281-2284.

Guillem, J. G., Wood, W. C., Moley, J. F., Berchuck, A., Karlan, B. Y., Mutch, D. G.,...Weitzel, J. N., et al. (2006). **ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.** *J Clin Oncol*, 24(28), 4642-4660. doi:10.1200/JCO.2005.04.5260

Guillem, J. G., Wood, W. C., Moley, J. F., Berchuck, A., Karlan, B. Y., Mutch, D. G.,...Weitzel, J. N., et al. (2006). **ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.** *Ann Surg Oncol*, 13(10), 1296-1321. doi:10.1245/s10434-006-9036-6

Jasperson, K. W., Lowstuter, K. J., & Weitzel, J. N. (2006). **Assessing the predictive accuracy of HMLH1 and HMSH2 mutation probability models.** *J Genet Couns*, 15(5), 339-347. doi:10.1007/s10897-006-9035-6

MacDonald, D. J., Sand, S., Kass, F., Blazer, K. R., Congleton, J., Craig, J., & Weitzel, J. N. (2006). **The power of partnership: Extending comprehensive cancer center expertise in clinical cancer genetics to community breast care centers.** *Seminars in Breast Disease*, 9, 39-47. doi:10.1053/j.sembd.2006.10.001

MacDonald, D. J., Sarna, L., Uman, G. C., Grant, M., & Weitzel, J. N. (2006). **Cancer screening and risk reducing behaviors of women seeking genetic cancer risk assessment for breast and ovarian cancers.** *Oncol Nurs Forum*, 33(2), E27-35. doi:10.1188/6.ONF.E27-E35

City of Hope

Division of Clinical Cancer Genetics

Publications

Ricker, C., Lagos, V. I., Feldman, N., Hiyama, S., Fuentes, S., Kumar, V., Gonzalez, K., Palomares, M. R., Blazer, K. R., Lowstuter, K. J., MacDonald, D. J., & Weitzel, J. N. (2006). **If we build it...Will they come? - Establishing a cancer genetics services clinic for an underserved predominantly Latina cohort.** *J Genet Couns*, 15(6), 505-514. doi:10.1007/s10897-006-9052-5

2005

Blazer, K. R., MacDonald, D. J., Ricker, C., Sand, S., Uman, G. C., & Weitzel, J. N. (2005). **Outcomes from intensive training in genetic cancer risk counseling for clinicians.** *Genet Med*, 7(1), 40-47. doi:10.1097/01.GIM.0000151154.27612.49

Cullinane, C. A., Lubinski, J., Neuhausen, S. L., Ghadirian, P., Lynch, H. T., Isaacs, C., Weber, B.,...Weitzel, J. N., et al. (2005). **The effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.** *Int J Cancer*, 117(6), 988-991. doi:10.1002/ijc.21273

Culver, J. O., Edwards, Q. T., MacDonald, D. J., & Weitzel, J. N. (2005). **USPSTF guidelines will miss BRCA families due to paternal inheritance or a truncated family tree.** *Ann Intern Med*, 143(5), 355. Retrieved from <http://www.annals.org/content/143/5/355.abstract/> reply#nnintmed_el_2247

Larson, G. P., Ding, Y., Cheng, L. S., Lundberg, C., Gagalang, V., Guillermo, R.,...Weitzel, J. N., MacDonald, D. J., et al. (2005). **Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHIT.** *Cancer Res*, 65(3), 805-814.

MacDonald, D. J., Sarna, L., Uman, G. C., Grant, M., & Weitzel, J. N. (2005). **Health beliefs of women with and without breast cancer seeking genetic cancer risk assessment.** *Cancer Nurs*, 28(5), 372-379.

Palomares, M. R., Paz, I. B., & Weitzel, J. N. (2005). **Genetic cancer risk assessment in the newly diagnosed breast cancer patient is useful and possible in practice.** *J Clin Oncol*, 23(13), 3165-3166. doi:10.1200/JCO.2005.05.157

Weitzel, J. N., Lagos, V. I., Blazer, K. R., Nelson, R., Ricker, C., Herzog, J., et al. (2005). **Prevalence of BRCA mutations and founder effect in high-risk Hispanic families.** *Cancer Epidemiol Biomarkers Prev*, 14, 1666-1671.

Weitzel, J. N., Robson, M., Pasini, B., Manoukian, S., Stoppa-Lyoneet, D., Lynch, H. T., et al. (2005). **A comparison of bilateral breast cancers in BRCA carriers.** *Cancer Epidemiol Biomarkers Prev*, 14(6), 1534-1538.

2004

Blazer, K. R., Grant, M., Sand, S. R., MacDonald, D. J., Uman, G. C., & Weitzel, J. N. (2004). **Effects of a cancer genetics education programme on clinicians knowledge and practice.** *J Med Genet*, 41(7), 518-522. doi:10.1136/jmg.2004.018234

City of Hope

Division of Clinical Cancer Genetics

Publications

Brenner, R. J., Weitzel, J. N., Hansen, N., & Boasberg, P. (2004). **Screening detected breast cancer in a man with BRCA2 mutation: Case report.** *Radiology*, 230(2), 553-555.

Jardines, L., Haffty, B. G., Doroshov, J. H., Fisher, P., & Weitzel, J. N. (2004). **Breast cancer overview: Risk factors, screening, genetic testing, and prevention.** In R. Pazdur, L. R. Coia, W. J. Hoskins & L. D. Wagman (Eds.), *Cancer management: A multidisciplinary approach medical, surgical & radiation oncology* (8th ed., pp. 165-190). Manhasset, New York: CMP Healthcare Media, Oncology Publishing Group.

MacDonald, D. J., & Weitzel, J. N. (2004). **Keeping current with risk reduction strategies for patients at hereditary cancer risk.** *International Society of Nurses in Genetics Newsletter*, 12(2), Pages 1-15.

Martinez, S. L., Herzog, J., & Weitzel, J. N. (2004). **Loss of five amino acids in BRCA2 is associated with ovarian cancer.** *J Med Genet*, 41(2), e18.

Nedelcu, R., Blazer, K. R., Schwerin, B. U., Gambol, P., Mantha, P., Uman, G. C., & Weitzel, J. N. (2004). **Genetic discrimination: The clinician perspective.** *Clin Genet*, 66(4), 311-317. doi:10.1111/j.1399-0004.2004.00303.x

Somlo, G., Frankel, P., Chow, W., Leong, L., Margolin, K., Morgan, R., Jr.,...Weitzel, J. N., et al. (2004). **Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy.** *J Clin Oncol*, 22(10), 1839-1848. doi:10.1200/CO.2004.10.147

Weitzel, J. N. (2004). **Evidence for advice: Reduction in risk of breast or ovarian cancer after salpingo-oophorectomy in carriers of BRCA1 or BRCA2 mutations.** *Breast Diseases: A Year Book Quarterly*, 14(4), 354-356.